These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30719508)

  • 21. Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.
    Schunselaar LM; Monkhorst K; van der Noort V; Wijdeven R; Peters D; Zwart W; Neefjes J; Baas P
    J Thorac Oncol; 2018 Oct; 13(10):1577-1587. PubMed ID: 29959059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence.
    Aramini B; Masciale V; Grisendi G; Bertolini F; Maur M; Guaitoli G; Chrystel I; Morandi U; Stella F; Dominici M; Haider KH
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells.
    Alhabbab RY
    Front Genet; 2020; 11():312. PubMed ID: 32391048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells.
    Spencer HL; Eastham AM; Merry CL; Southgate TD; Perez-Campo F; Soncin F; Ritson S; Kemler R; Stern PL; Ward CM
    Mol Biol Cell; 2007 Aug; 18(8):2838-51. PubMed ID: 17507657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
    Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
    J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The evolving concept of cancer stem-like cells in thyroid cancer and other solid tumors.
    Hardin H; Zhang R; Helein H; Buehler D; Guo Z; Lloyd RV
    Lab Invest; 2017 Oct; 97(10):1142-1151. PubMed ID: 28394318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches.
    Pan Q; Li Q; Liu S; Ning N; Zhang X; Xu Y; Chang AE; Wicha MS
    Stem Cells; 2015 Jul; 33(7):2085-92. PubMed ID: 25873269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 5T4 oncofetal glycoprotein does not act as a general organizer of the CXCL12 system in cancer cells.
    Puchert M; Koch C; Engele J
    Exp Cell Res; 2018 Mar; 364(2):175-183. PubMed ID: 29408206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
    Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
    Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.
    Mulryan K; Ryan MG; Myers KA; Shaw D; Wang W; Kingsman SM; Stern PL; Carroll MW
    Mol Cancer Ther; 2002 Oct; 1(12):1129-37. PubMed ID: 12481437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer Stem Cells: Acquisition, Characteristics, Therapeutic Implications, Targeting Strategies and Future Prospects.
    Yadav AK; Desai NS
    Stem Cell Rev Rep; 2019 Jun; 15(3):331-355. PubMed ID: 30993589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotargeting of Cancer Stem Cells.
    Köseer AS; Di Gaetano S; Arndt C; Bachmann M; Dubrovska A
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
    Katoh M
    Int J Oncol; 2017 Nov; 51(5):1357-1369. PubMed ID: 29048660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolving Strategies for Therapeutically Targeting Cancer Stem Cells.
    Talukdar S; Emdad L; Das SK; Sarkar D; Fisher PB
    Adv Cancer Res; 2016; 131():159-91. PubMed ID: 27451127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification, Culture and Targeting of Cancer Stem Cells.
    Herreros-Pomares A
    Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trailblazing perspectives on targeting breast cancer stem cells.
    Li J; Qi D; Hsieh TC; Huang JH; Wu JM; Wu E
    Pharmacol Ther; 2021 Jul; 223():107800. PubMed ID: 33421449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Cancer Stem Cell Markers or Pathways: A Potential Therapeutic Strategy for Oral Cancer Treatment.
    Lee JW; Lee HY
    Int J Stem Cells; 2021 Nov; 14(4):386-399. PubMed ID: 34711702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted therapy against cancer stem cells.
    Yang T; Rycaj K
    Oncol Lett; 2015 Jul; 10(1):27-33. PubMed ID: 26170972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.
    Xu Y; Morales AJ; Cargill MJ; Towlerton AMH; Coffey DG; Warren EH; Tykodi SS
    Cancer Immunol Immunother; 2019 Dec; 68(12):1979-1993. PubMed ID: 31686124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.